Browse evidence-based analysis of health-related claims and assertions
People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had higher levels of a growth-related hormone called IGF-1. This finding is from the abstract summary - full study details were not available
Correlational
People with HIV who have belly fat and are on medication to control the virus who took tesamorelin did not show a significant improvement in thinking skills compared to those who received usual care after six months. This finding is from the abstract summary - full study details were not available
People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had a waist size that was about 2.7 centimeters smaller on average compared to those who didn't, and this difference was statistically significant. This finding is from the abstract summary - full study details were not available
Stopping tesamorelin causes the positive effects to go away in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available
Descriptive
Taking tesamorelin makes people with HIV feel better about their belly appearance. This finding is from the abstract summary - full study details were not available
Tesamorelin helps lower blood fat levels in people with HIV-related body changes. This finding is from the abstract summary - full study details were not available
Tesamorelin doesn't significantly change the fat under the skin in people with HIV-related body shape changes. This finding is from the abstract summary - full study details were not available
Taking tesamorelin is linked to less belly fat in people with HIV who have body shape changes. This finding is from the abstract summary - full study details were not available
Adding omentum removal to gastric bypass surgery didn't change levels of hormones produced by fat tissue (adipokines) in women with severe obesity and metabolic syndrome.
Non-diabetic women with severe obesity and metabolic syndrome who had gastric bypass surgery with omentum removal had better overall insulin function (disposition index) at 6 and 12 months compared to those who only had the bypass.
For non-diabetic women with severe obesity and metabolic syndrome who had gastric bypass surgery, adding omentum removal helped maintain their body's insulin response to sugar after one year, while those without it saw a decline.
Women with severe obesity and metabolic syndrome who had gastric bypass surgery with omentum removal had lower levels of a marker for inflammation (CRP) after one year compared to those who only had the bypass.
For women with severe obesity and metabolic syndrome who had gastric bypass surgery, adding the removal of the omentum fat led to more weight loss over time compared to just the bypass alone.
In people with HIV and belly fat, the amount of visceral fat didn't correlate with liver enzyme AST levels when other factors like sex and hepatitis were considered.
HIV patients with high liver enzymes who lost belly fat from tesamorelin were 2.5 times more likely to have normal ALT levels than those who didn't lose fat, even after accounting for other factors.
Quantitative
Whether people with HIV had hepatitis or not didn't change the relationship between losing belly fat and improving liver enzymes.
When people with HIV and belly fat lost fat from a placebo pill, their liver enzymes didn't improve, but when they lost fat from tesamorelin, their liver enzymes did improve.
In people with HIV and belly fat, higher amounts of visceral fat were linked to higher liver enzyme levels even when accounting for other factors like sex and hepatitis.
Even after stopping tesamorelin, people with HIV who had lost belly fat still had better liver enzyme levels for a full year, even though some fat came back.
HIV patients with high liver enzymes who lost enough belly fat from tesamorelin were more than twice as likely to have their ALT levels return to normal compared to those who didn't lose much fat.
For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.
People with HIV and fatty liver disease who were on INSTI drugs had similar body measurements at the start of the study compared to those not on INSTIs.
In the study, most people with HIV and fatty liver disease on INSTI drugs were taking dolutegravir, which made up 41% of those on INSTIs.
People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.
Causal